查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1621347

帶狀皰疹疫苗市場：按產品、類型和分銷管道 - 2025-2030 年全球預測

Shingles Vaccine Market by Product (SkyZoster, Zostavax, Shingrix), Type (Live Attenuated Vaccine, Recombinant Vaccine), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

帶狀皰疹疫苗市場 2023 年估值為 17.3 億美元，預計 2024 年將達到 18.7 億美元，複合年成長率為 8.11%，到 2030 年將達到 29.9 億美元。

全球帶狀皰疹疫苗市場的定義特別著重於預防 50 歲及以上族群的帶狀皰疹感染。帶狀皰疹是由水痘帶狀皰疹病毒（水痘）重新運作引起的，需要接種疫苗以減少帶狀皰疹後遺症神經痛等嚴重併發症。這個市場是由老年人口的增加、疾病意識的增強以及疫苗技術的進步所推動的。主要應用包括老年保健和免疫力缺乏患者管理。最終用戶採用範圍包括醫院、診所和專業醫療中心。成長要素包括積極的政府措施、有利的報銷政策和醫療保健支出的增加。機會存在於疫苗接種率低的新興市場、增加疫苗庫存目標的機會以及創新交付方法的夥伴關係。目前的建議是擴大教育計畫以提高吸收率，並採取針對高風險族群的行銷策略。然而，高昂的製造成本、較高的監管障礙以及對疫苗安全性的懷疑正在阻礙市場的快速滲透。此外，還存在疫苗分配中的物流問題、疫苗猶豫的影響以及在醫療保健產品方面享有盛譽的大型製藥公司的競爭等挑戰。值得關注的創新領域包括探索長效疫苗配方、改善免疫反應的新佐劑系統，以及可提供更快生產時間和擴充性的基於 mRNA 的疫苗技術。策略性措施包括聯合研發和投資基因工程疫苗，以提供全面的保護，同時最大限度地減少副作用。儘管市場競爭激烈，有GlaxoSmithKline Plc和默克等大公司的存在，但該公司可以透過利用疫苗開發中的人工智慧等技術進步，在不斷成長的領域中開拓出一席之地。潛力。

主要市場統計
基準年[2023] 17.3億美元
預計年份 [2024] 18.7億美元
預測年份 [2030] 29.9億美元
複合年成長率（%） 8.11%

市場動態：快速發展的帶狀皰疹疫苗市場的關鍵市場洞察

帶狀皰疹疫苗市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性病盛行率增加
    • 世界老年人口的增加
    • 人們對帶狀皰疹健康風險的認知不斷提高，對疫苗接種的興趣日益濃厚
  • 市場限制因素
    • 疫苗研發需要大量資金
  • 市場機會
    • 帶狀皰疹疫苗的持續研發計劃
    • 全球公共衛生支出大幅增加
  • 市場挑戰
    • 與帶狀皰疹疫苗相關的副作用

波特的五力：駕馭帶狀皰疹疫苗市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解帶狀皰疹疫苗市場的外部影響

外部宏觀環境因素在塑造帶狀皰疹疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解帶狀皰疹疫苗市場的競爭格局

帶狀皰疹疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣帶狀皰疹疫苗市場供應商的績效評估

FPNV 定位矩陣是評估帶狀皰疹疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪帶狀皰疹疫苗市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，帶狀皰疹疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病增加
      • 世界各地的老年人口正在增加
      • 提高對帶狀皰疹健康風險的認知並更加關注疫苗接種
    • 抑制因素
      • 疫苗研發需要大量資金
    • 機會
      • 關於帶狀皰疹疫苗的持續研究和開發工作
      • 全球公共衛生支出大幅增加
    • 任務
      • 與帶狀皰疹疫苗相關的副作用
  • 市場區隔分析
    • 產品：Shingrix 對於提高安全性日益重要
    • 類型：了解重組帶狀皰疹疫苗的好處
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章帶狀皰疹疫苗市場：依產品

  • 天空之星
  • 佐斯塔瓦克斯
  • 定序

第7章帶狀皰疹疫苗市場：依類型

  • 減毒活疫苗
  • 重組疫苗

第8章帶狀皰疹疫苗市場：依通路分類

  • 保健中心
  • 藥局

第9章美洲帶狀皰疹疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區帶狀皰疹疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲帶狀皰疹疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Dynavax 開始有前途的帶狀皰疹疫苗 Z-1018 的臨床試驗
    • 科興生物將 PROVARIX 疫苗的核准擴大到青少年和成人，以增加公共衛生效益
    • 葛蘭素史克 (GSK) 將 Shingrix 疫苗的核准擴大到中國的年輕人，旨在產生更廣泛的公共衛生影響
  • 戰略分析和建議

公司名單

  • Astellas Pharma Inc.
  • Barinthus Biotherapeutics plc
  • Bavarian Nordic
  • Biogenetech Co., Ltd.
  • CanSino Biologics Inc.
  • CSL Limited
  • Curevo Inc.
  • Daiichi Sankyo Company, Limited
  • Dynavax Technologies Corporation
  • Emergent Biosolutions Inc.
  • GeneOne Life Science, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Recbio Technology Co., Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sinovac Biotech Ltd.
  • SK Chemicals
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • VBI Vaccines Inc.
Product Code: MRR-563BF1FCEEC2

The Shingles Vaccine Market was valued at USD 1.73 billion in 2023, expected to reach USD 1.87 billion in 2024, and is projected to grow at a CAGR of 8.11%, to USD 2.99 billion by 2030.

The global shingles vaccine market is defined by its focus on the prevention of herpes zoster infections, particularly among individuals aged 50 and above. Shingles, caused by the reactivation of the varicella-zoster virus (chickenpox), necessitates vaccination to mitigate severe complications such as postherpetic neuralgia. The market is driven by an increasing aged population, rising awareness about the disease, and advancements in vaccine technology. Key applications include its use in elderly healthcare and immunocompromised patient management. End-user adoption spans across hospitals, clinics, and specialty healthcare centers. Growth factors include robust government initiatives, favorable reimbursement policies, and escalating healthcare expenditure. Opportunities arise from emerging markets with low vaccination rates, opportunities for enhanced vaccine strain targeting, and partnerships for innovative delivery methods. Current recommendations focus on expanding educational programs to boost uptake and employing targeted marketing strategies to reach high-risk demographics. However, limitations include high production costs, stringent regulatory hurdles, and public skepticism over vaccine safety that may hamper rapid market penetration. Additional challenges involve logistical issues in vaccine distribution, impact of vaccine hesitancy, and competition from existing pharmaceutical giants with entrenched healthcare products. Remarkable areas for innovation include research into long-lasting vaccine formulations, novel adjuvant systems to improve immune response, and mRNA-based vaccine technologies, which can offer faster production times and scalability. The strategic movement involves collaborative R&D and investment in genetically engineered vaccines that provide comprehensive coverage with minimal side effects. The market exhibits a competitive nature marked by the presence of major players like GlaxoSmithKline and Merck & Co., but it also presents a dynamic landscape with potential for new entrants who can leverage technological advancements, such as artificial intelligence for vaccine development, to carve out a niche in a growing sector.

KEY MARKET STATISTICS
Base Year [2023] USD 1.73 billion
Estimated Year [2024] USD 1.87 billion
Forecast Year [2030] USD 2.99 billion
CAGR (%) 8.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Shingles Vaccine Market

The Shingles Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases
    • Rising number of geriatric population worldwide
    • Rising awareness about shingles health risks and growing focus on immunization
  • Market Restraints
    • High capital requirements for vaccine development
  • Market Opportunities
    • Ongoing Research & development initiatives on shingles vaccines
    • Significantly increasing public health expenditure worldwide
  • Market Challenges
    • Adverse effects associated with shingles vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Shingles Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Shingles Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Shingles Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Shingles Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Shingles Vaccine Market

A detailed market share analysis in the Shingles Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Shingles Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Shingles Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Shingles Vaccine Market

A strategic analysis of the Shingles Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Shingles Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Barinthus Biotherapeutics plc, Bavarian Nordic, Biogenetech Co., Ltd., CanSino Biologics Inc., CSL Limited, Curevo Inc., Daiichi Sankyo Company, Limited, Dynavax Technologies Corporation, Emergent Biosolutions Inc., GeneOne Life Science, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Sanofi S.A., Sinovac Biotech Ltd., SK Chemicals, Takeda Pharmaceutical Company Limited, Valneva SE, and VBI Vaccines Inc..

Market Segmentation & Coverage

This research report categorizes the Shingles Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across SkyZoster, Zostavax, and Shingrix.
  • Based on Type, market is studied across Live Attenuated Vaccine and Recombinant Vaccine.
  • Based on Distribution Channel, market is studied across Healthcare Centers and Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases
      • 5.1.1.2. Rising number of geriatric population worldwide
      • 5.1.1.3. Rising awareness about shingles health risks and growing focus on immunization
    • 5.1.2. Restraints
      • 5.1.2.1. High capital requirements for vaccine development
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research & development initiatives on shingles vaccines
      • 5.1.3.2. Significantly increasing public health expenditure worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with shingles vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising significance of Shingrix for higher safety profile
    • 5.2.2. Type: Understanding the benefits of recombinant shingles vaccines
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Shingles Vaccine Market, by Product

  • 6.1. Introduction
  • 6.2. SkyZoster
  • 6.3. Zostavax
  • 6.4. Shingrix

7. Shingles Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Live Attenuated Vaccine
  • 7.3. Recombinant Vaccine

8. Shingles Vaccine Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Healthcare Centers
  • 8.3. Pharmacies

9. Americas Shingles Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Shingles Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Shingles Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Dynavax Begins Clinical Trial for Promising Shingles Vaccine, Z-1018
    • 12.3.2. Sinovac Biotech Ltd. Expands PROVARIX Vaccine Approval to Adolescents and Adults, Targeting Increased Public Health Benefits
    • 12.3.3. GSK Expands Shingrix Vaccine Approval to Younger Adults in China, Targets Broader Public Health Impact
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. Barinthus Biotherapeutics plc
  • 3. Bavarian Nordic
  • 4. Biogenetech Co., Ltd.
  • 5. CanSino Biologics Inc.
  • 6. CSL Limited
  • 7. Curevo Inc.
  • 8. Daiichi Sankyo Company, Limited
  • 9. Dynavax Technologies Corporation
  • 10. Emergent Biosolutions Inc.
  • 11. GeneOne Life Science, Inc.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Inovio Pharmaceuticals, Inc.
  • 15. JCR Pharmaceuticals Co., Ltd.
  • 16. Jiangsu Recbio Technology Co., Ltd.
  • 17. Merck KGaA
  • 18. Moderna, Inc.
  • 19. Pfizer Inc.
  • 20. Sanofi S.A.
  • 21. Sinovac Biotech Ltd.
  • 22. SK Chemicals
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Valneva SE
  • 25. VBI Vaccines Inc.

LIST OF FIGURES

  • FIGURE 1. SHINGLES VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. SHINGLES VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SHINGLES VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SHINGLES VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SKYZOSTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTAVAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SHINGRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HEALTHCARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2023